Review

Mesenchymal Stem Cells as Feeder Cells for Pancreatic Islet Transplants

Valeria Sordi, Lorenzo Piemonti

Manuscript submitted July 20, 2010; resubmitted August 7, 2010; accepted August 9, 2010.

Keywords: stem cell, feeder, islet, co-transplantation, revascularization, bone marrow, immunomodulation

Abstract

Allogeneic islet transplantation serves as a source of insulin-secreting beta-cells for the maintenance of normal glucose levels and treatment of diabetes. However, limited availability of islets, high rates of islet graft failure, and the need for life-long non-specific immunosuppressive therapy are major obstacles to the widespread application of this therapeutic approach. To overcome these problems, pancreatic islet transplantation was recently suggested as a potential target of the "therapeutic plasticity" of adult stem cells. In fact, new results suggest that stem/precursor cells, and mesenchymal stem cells in particular, co-transplanted with islets can promote tissue engraftment and beta-cell survival via bystander mechanisms, mainly exerted by creating a milieu of cytoprotective and immunomodulatory molecules. This evidence consistently challenges the limited view that stem/precursor cells work exclusively through beta-cell replacement in diabetes therapy. It proposes that stem cells also act as "feeder" cells for islets, and supporter of graft protection, tissue revascularization, and immune acceptance. This article reviews the experience of using stem cell co-transplantation as strategy to improve islet transplantation. It highlights that comprehension of the mechanisms involved will help to identify new molecular targets and promote development of new pharmacological strategies to treat type 1 and type 2 diabetes patients.

Fulltext: HTML , PDF (937KB)

This article has been cited by other articles:

	The great migration of bone marrow-derived stem cells toward the ischemic brain: therapeutic implications for stroke and other neurological disorders Borlongan CV, Glover LE, Tajiri N, Kaneko Y, Freeman TB Prog Neurobiol 2011. 95(2):213-228
	New hope for type 2 diabetics: targeting insulin resistance through the immune modulation of stem cells Zhao Y, Jiang Z, Guo C Autoimmun Rev 2011. 11(2):137-142
	A step-up approach for cell therapy in stroke: translational hurdles of bone marrow-derived stem cells Glover LE, Tajiri N, Weinbren NL, Ishikawa H, Shinozuka K, Kaneko Y, Watterson DM, Borlongan CV Transl Stroke Res 2011. In press
	Current status of immunomodulatory and cellular therapies in preclinical and clinical islet transplantation Chhabra P, Brayman KL J Transplant 2011. 2011:637692
	Beta-cell generation: can rodent studies be translated to humans? Carlotti F, Zaldumbide A, Ellenbroek JH, Spijker HS, Hoeben RC, de Koning EJ J Transplant 2011. 2011:892453
	Human placenta-derived mesenchymal stem cells and islet-like cell clusters generated from these cells as a novel source for stem cell therapy in diabetes Kadam S, Muthyala S, Nair P, Bhonde R Rev Diabet Stud 2010. 7(2):168-182